Analysis Of Pyronaridine And Pyronaridine

Tetraphosphate Using High Performance

Liquid Chromatography And High Resolution

Nuclear Magnetic Resonance Spectroscopy by Saurajen Pillay, Shubhadra Pillay
ANALYSIS OF PYRONARIDINE A{;JO PYRONARIDINE 
TETRAPHOSPHATE USING HIGH PERFORMANCE 
LIQUID CHROMATOGRAPHY AND HIGH RESOLUTION 
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 
by 
SHUBHADRA PILLAY AlP SAURAJEN PILLAY 
Thesis submitted in fulfilment of the requirements 
for the degree of 
Masters of Science 
July 2006 
ACKNOWLEDGMENTS 
Many talented instructors, students and lab assistants provided helpful 
comments and thoughtful suggestions at each stage throughout my project. I am 
sincerely grateful to my supervisor, Professor V. Navaratnam for his valuable 
assistance and advice throughout the course of my project and report. His 
encouragement and support has helped me learn what a true researcher is made of. I 
would also like to express my gratitude to my co-supervisor, Associate Professor 
Dr.Mas Rosemal Hakim Bin Mas Haris for his constant support, enthusiasm, guidance 
and exceptional role that he has played in the course of my project. He has helped me 
discover my interest in the field of organic structural analysis by his continuing insight 
and motivation. My appreciation also goes to my co-supervisor from the Centre for 
Drug Research, Professor. Sharif Mahsufi Mansor for his continuing moral support and 
encouragements. 
It is the experience and profeSSional help of the technical staff that makes the 
journey of a graduate student a smooth one. I would not have been able to learn so 
much or achieve what I have if not for their untiring assistance. Here I would like to 
record my heartfelt appreciation to Mr. Zahari Bin Othman for always maintaining a 
cheerful environment in his NMR section and untiring effort in teaching me how to 
operate the NMR instrument. I would also like to thank Mr. Simon Aw Yeong of the IR 
SECTION, Mr. Ong Chin Hin (CHN section) and Mr. Yee Chin Leng (Mass Spec 
section) from Chemistry School for their help. 
Mr. Asokan Muniandy from Centre for Drug Research has not only provided 
technical assistance but also has proven to be a true friend in times of need. I would 
like to express my warmest gratitude to him for always being positive and cheerful in aU 
11 
situations. I would like to thank Mr.Narhari Thakorlal and Mr. Aru for their assistance in 
the lab. My appreciation to all the administrative staff at Centre for Drug Research. 
My sincerest gratitude to HISCO (Malaysia) Sdn. Bhd., JEOL (Malaysia) Sdn. 
Bhd. and Bruker Biospin AG for providing technical support in terms of spectral 
acquisition. I would also like to thank Dr. Helena Kovacs of Bruker Biospin AG, for her 
valuable discussions and insights on NMR spectral data. 
I have been very lucky to have excellent friends in the place of my study. I 
would like to express my warmest gratitude to Miss. Lai Choon Sheen, Miss Wong 
Peng Lin, Miss Theepa Asualingam, Mr. Mahbubuzzaman and Mr. G.venkatesh. They 
have made my experience here memorable, always cheering me whenever I faced 
difficulties and never failing to provide help when needed. 
III 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS 
TABLE OF CONTENTS 
LIST OF TABLES 
LIST OF FIGURES 
LIST OF SYMBOLS 
LIST OF ABBREVIATIONS 
ABSTRAK 
ABSTRACT 
CHAPTER ONE: INTRODUCTION 
1.1 Malaria 
1.2 Status of Malaria in Malaysia 
1.3 Malaria Pathology 
1.3.1 Species 
1.3.2 Life Cycle 
1.4 Biological classification of drugs 
1.5 Antimalarial Drugs 
1.5.1 Quinine 
1.5.2 Chloroquine 
1.5.3 Mefloquine 
1.5.4 Halofantrine 
1.5.5 Amodiaquine 
1.5.6 Pyrimethamine/ Sulphadoxine 
1.5.7 Chloroguanide 
1.5.8 Artemisinin Derivatives 
1.5.9 Lumefantrine 
IV 
Page 
ii 
iv 
xi 
xii 
xvi 
xvi 
xviii 
xx 
1 
1 
4 
4 
4 
7 
8 
8 
9 
10 
11 
11 
12 
12 
13 
14 
1.5.10 Primaquine 14 
1.6 Pyronaridine Tetraphosphate (PNDT) 16 
1.6.1 Introduction 16 
1.6.2 Chemistry of Pyronaridine (PND) 18 
1.6.3 Synthesis of PND 18 
1.6.4 Analysis of PND 21 
1.6.5 In vitro and In vivo Activities 24 
1.6.6 Pharmacokinetics 27 
1.6.7 Efficacy studies 28 
1.6.8 PND and MDR-reversal 29 
1.6.9 Toxicity 29 
1.7 Methods of Analysis 31 
1.7.1 Separation Techniques 31 
1.7.1 a Precipitation 31 
1.7.1 b Continuous Extraction 31 
1.7.1 c Chromatographic Separations 32 
1.7.2 Chromatography 32 
1.7.2a High Performance Liquid Chromatography 32 
1.7.2b Components 32 
1.8 Identification and Characterization 34 
1.8.1 Infrared Spectroscopy 34 
1.8.2 Nuclear Magnetic Resonance 34 
1.8.2.1 Proton Magnetic Resonance Spectrometry 34 
1.8.2.2 13C NMR Experiment 35 
1.8.2.3 DEPT Experiment 35 
1.8.2.4 Correlation Spectroscopy (COSY) Experiment 35 
1.8.2.5 Double Quantum Filtered 1H_1H COSY 36 
v 
1.8.2.6 Total correlation spectroscopy (TOCSY) Experiment 37 
1.8.2.7 Heteronuclear Single-Bond Correlation Spectroscopy 38 
1.8.2.8 Heteronuclear Multiple Bond Correlation (HMBC) 39 
1.8.2.9 Deuterium Exchange 40 
1.8.2.10 The Nuclear Overhauser Effect (NOE) 40 
1.8.3 DynamiC NMR Spectroscopy (DNMR) 41 
1.8.3.1 The Coalescence Temperature Tc and 
Corresponding Rate Constant kc 41 
1.8.3.2 The Free Enthalpy of Activation ,0,.G 42 
1.8.3.3 Intra- and Intermolecular Hydrogen Bonding 43 
1.8.4 Mass Spectrometry 43 
1.9 Aim of Study 44 
CHAPTER TWO: MATERIALS AND PROCEDURE 46 
2.1 Materials and Reagents 46 
2.2 Instruments 47 
2.3 Standards 48 
2.4 High Performance Liquid Chromatography 48 
2.4.1 Preparation of Standards 48 
2.4.2 Preparation of Sample Solutions 49 
2.4.3 Preparation of Buffer Solution 49 
2.4.4 Mobile phase 49 
2.4.5 Detector 49 
2.4.6 Column 50 
" A .., Integrator 50 L.'t.f 
2.5 Verification of Peaks Present 51 
2.6 Optimisation of Component B 51 
2.7 Methods of Extraction 52 
VI 
2.7.1 Isolation of Pyronaridine (PND) from its salt (PNDT) 
2.7.2 Continuous Extraction 
2.7.3 Liquid Extraction 
2.8 Identification and Characterisation 
2.8.1 Infrared (I R) 
2.8.1.1 Sample Preparation 
2.8.1.2 Experimental 
2.8.2 Nuclear Magnetic Resonance (NMR) 
2.8.2.1 Sample preparation 
2.8.2.2 Experimental 
2.8.2.2.10ne- And Two-Dimensional NMR Spectroscopy 
2.8.2.2.2 Dynamic NMR (Variable temperature, 
mixed solvents and deuterium exchange) 
Spectroscopy 
2.8.3 Mass Spectrometry (MS) 
2.8.4 Elemental Analysis 
2.8.5 Melting Point 
2.9 Silanisation of Glassware 
2.10 Summary of Methodology 
CHAPTER THREE: RESULTS 
3.1 High Performance Liquid Chromatography Analysis of PNDT, PND 
and Component B 
3.1.1 Verification of Peaks Present 
3.1.1 a Pyronaridine Tetraphosphate 
3,1.1 b Pyronaridine 
3.1.2 Optimisation of Component B 
3.1.3 Extraction 
VIl 
52 
53 
53 
54 
54 
54 
55 
55 
55 
56 
56 
57 
58 
58 
58 
59 
59 
61 
61 
61 
64 
67 
71 
3.2 
3.3 
3.4 
3.1.3a Isolation of PND 
3.1.3b Continuous Extraction 
3.1.3c Liquid Extraction 
71 
71 
73 
76 
76 
78 
78 
Melting Point 
Elemental (C, Hand N) Analysis of PNDT, PND and Component B 
Spectral Studies On PNDT, PND and Component B 
3.4.1 Mass Spectrometry 
3.4.2 Infrared (IR) 82 
3.4.3 Nuclear Magnetic Resonance 89 
3.4.3.1 Pyronaridine in Dimethylsulfoxide-d6 (DMSO) 90 
3.4.3.1a Analysis of Proton NMR Spectrum 90 
3.4.3.1 b Analysis of Correlation Spectroscopy 
(COSY) NMR Spectrum 94 
3.4.3.1 c Analysis of Total Correlation 
Spectroscopy (TOCSY) NMR Spectrum 97 
3.4.3.1d Analysis of Carbon NMR Spectrum 99 
3.4.3.1e Analysis of Heteronuclear Single 
Quantum Coherence (HSQC) NMR Spectrum 101 
3.4.3.1f Analysis of Heteronuclear Multiple 
Bond Correlation (HMBC) NMR Spectrum 103 
3.4.3.2 Pyronaridine in CDCI3 107 
3.4.3.3 Nuclear Overhauser Effect Spectroscopy (NOESY) 112 
3.4.3.4 Pyronaridine Tetraphosphate in DMSO 115 
3.4.3.4a Analysis of Proton NMR Spectrum 115 
3.4.3.4b Analysis of COSY NMR Spectrum 117 
3.4.3.4c Analysis of TOCSY NMR Spectrum 120 
3.4.3.4d Analysis of HSQC NMR Spectrum 120 
3.4.3.4e Analysis of HMBC NMR Spectrum 123 
VIII 
3.4.3.5 PNDT in D20 
3.4.3.5a Proton Assignments 
3.4.3.5b Analysis of COSY and TOCSY NMR 
Spectrum 
3.4.3.5c Analysis of DEPT NMR Spectrum 
3.4.3.5d Analysis of HSQC NMR Spectrum 
3.4.3.5e Analysis of HMBC NMR Spectrum 
3.4.3.6 Component B 
3.4.4 Dynamic (Variable temperature, mixed 
solvents and deuterium exchange) NMR Studies 
3.4.4.1 Pyronaridine Tetraphosphate 
3.4.4.1 a NMR study at temperature range of 25-90 DC 
3.4.4.1 b NMR study at temperature range of 5-15 DC 
3.4.4.2 Pyronaridine 
3.4.4.2a NMR study at temperature range 25 to -55 DC 
3.4.4.3 Mixed Solvent 
3.4.4.4 Deuterium Exchange 
CHAPTER FOUR: DISCUSSION 
CHAPTER FIVE: CONCLUSION 
REFERENCES 
APPENDICES 
125 
125 
128 
130 
130 
133 
137 
142 
142 
144 
151 
154 
154 
156 
161 
163 
168 
170 
Appendix A: Empirical Calculations for Pyronaridine (PND) 180 
Appendix B: Chemical shifts of Pyronaridine (PND) predicted using CS Office 190 
Appendix C: Protocol of the 13C NMR Estimation 192 
Appendix D: NMR Spectrum of PND in DMSO 203 
Appendix E: NMR Spectrum of PND in CDCb 206 
IX 
Appendix F: NMR Spectrum of PNDT in DMSO 
Appendix G: NMR Spectrum of PNDT in D20 
x 
207 
209 
Table 1.1 
Table 1.2 
Table 3.1 
Table 3.2 
Table 3.3 
Table 3.4 
Table 3.5 
Table 3.6 
Table 3.7 
Table 3.8 
Table 3.9 
LIST OF TABLES 
Distribution of the different human malaria species in Malaysia 
for 1995 and 1999 (Singh & Singh 2001) 
Summary of methods of analysis for Pyronaridine 
Tetraphosphate 
Chromatographic data of pyronaridine tetraphosphate (PNDT) 
and pyronaridine (PND) in different solvents to verify the 
presence of component B. 
Chromatographic data for the optimisation of component B 
through exposure of pyronaridine tetraphosphate (PNDT) 
to different conditions. 
Elemental analysis data (CHN) of Pyronaridine tetraphosphate 
(PNDT), Pyronaridine (PND) and Component B 
Mass spectral data of PND, PNDT and component B 
Infrared spectral data of Pyronaridine (PND), Pyronaridine 
tetraphosphate (PNDT), and component B 
lH and 13C NMR chemical shift values of Pyronaridine (PND) 
in DMSOb and CDCbb, literature and Tl values (in seconds) 
lH and 13C NMR chemical shift values of PNDT in DMSOa and 
D20 b and T1 values (in seconds) 
1H and 13C chemical shift values of Pyronaridine (PND) in 
CDCI3 and DMSO in comparison to Component Bin DMSO. 
Coupling constant calculated in Hz. 
1H NMR Chemical shift of pyronaridine tetra phosphate (PNDT) in 
0 20 at temperature range of 5-65°C 
xi 
Page 
3 
23 
66 
68 
77 
81 
87 
111 
136 
141 
153 
LIST OF FIGURE 
Page 
Figure 1.1 Schema of the Life Cycle of Malaria 6 
Figure 1.2 Structure of main antimalarial drugs 15 
Figure 1.3 Pyronaridine (2-methoxy-7 -chloro-1 0-[3' ,5' -bis-(pyrrolidinyl-1-
1 methyl)-4' -hydroxyanilino]benzo[b ]-1 ,5-napthyridines) 17 
Figure 1.4 Schematic diagram of synthesis of PND and its simplified 
structural formula 20 
Figure 2.1 Flow chart of the methodology employed in this thesis 60 
Figure 3.1 Chromatograms of pyronaridine tetraphosphate (PNDT) in 
a.)Water- B at 9.46, X at 19.17, Y at 21.56; b.) DMSO- B 
at 9.52, X at 19.39, Y at 21.82; c.) Methanol- B at 10, X at 21.19, 
Y at 24.32 63 
Figure 3.2 Chromatogram of PND in a.) DMSO- B at 12.61, X at 26.59 
and Y at 30.10; and b.) Methanol- B at 12.64, X at 26.33 and Y 
at 29.85 min 65 
Figure 3.3a Chromatogram of PNDT in different conditions for optimising 
component B, a.) PNDT powder exposed to humidity (45°C) for 
15 days, b.) PNDT powder exposed to UV light for 15 days, 
both samples dissolved in methanol. 69 
Figure 3.3b Chromatogram of PNDT in different conditions for optimising 
component B, a.) PNDT solution in H20 exposed to UV light for 
15 days, b.) PNDT solution in Methanol exposed to UV light for 
15 days 70 
Figure 3.4 Chromatograms of continuous extraction (soxhlet) using 
a.) To!uene and b.) Hexane 72 
XII 
Figure 3.5 Chromatogram of liquid extraction of component Busing 
a.) Toluene and b.) Heptane c.) Hexane 74 
Figure 3.6 Stack plot of a.) PNDT b.) PND and c.) Component B 
in Methanol 75 
Figure 3.7 Mass spectrum of pyronaridine (PND) 79 
Figure 3.8 Mass spectrum of component B 80 
Figure 3.9 Infrared spectra of Pyronaridine (PND) 84 
Figure 3.10 Infrared spectra of Pyronaridine tetraphosphate (PNDT) 85 
Figure 3.11 Infrared spectra of Component B (extracted from PND) 86 
Figure 3.12 1H NMR spectrum of PND in DMSO 
(acquired using JNM-ECA, 600 MHz) 93 
Figure 3.13 COSY spectrum of PND in DMSO with an expansion of 
the aromatic region (acquired using JNM-ECA, 600 MHz) 96 
Figure 3.14 Expansion of the aromatic region for TOCSY spectrum 
of PND in DMSO (full spectrum in Appendix D) 98 
Figure 3.15 13C Spectrum of PND in DMSO 
(acquired using JNM-ECA, 600 MHz) 100 
Figure 3.16 HSQC spectrum of PND in DMSO, a.) aliphatic region 
and b.) aromatic region (acquired using JNM-ECA, 600 MHz) 102 
Figure 3.17 HMBC spectrum of PND in DMSO (aromatic region only). 
The complete spectrum is given in Appendix D 
(acquired using JNM-ECA, 600 MHz) 106 
Figure 3.18 'H NMR spectrum of PND in CDCI3 
(acquired using JNM-ECA, 600 MHz) 109 
Figure 3.19 TOCSY spectrum of Pyronaridine (PND) in CDCI3 
(Aromatic region only, full spectrum given in Appendix E) 
(acquired using JNM-ECA, 600 MHz) 110 
Figure 3.20 NOE correlations of Pyronaridine (PND) in DMSO 114 
XIII 
Figure 3.21 1H NMR spectrum of Pyronaridine Tetraphosphate 
(PNDT) in DMSO (acquired using JNM-ECA, 600 MHz) 117 
Figure 3.22 COSY spectrum of Pyronaridine Tetraphosphate (PNDT) in 
DMSO with the expansion of the aromatic region 
(acquired using JNM-ECA, 600 MHz) 119 
Figure 3.23 HSQC NMR Spectrum of Pyronaridine Tetraphosphate (PNDT) 
in DMSO (acquired using JNM-ECA, 600 MHz) 122 
Figure 3.24 1H NMR spectrum of Pyronaridine Tetraphosphate (PNDT) 
in D20 (Varian INOVA, 600 MHz) 127 
Figure 3.25 COSY spectrum of PNDT in D20, a.) aliphatic and 
b.)aromatic region (Varian INOVA, 600 MHz) 129 
Figure 3.26 DEPT spectra of Pyronaridine Tetraphosphate (PNDT) in 
D20 (Varian INOVA, 600 MHz) 131 
Figure 3.27 HSQC spectrum of PNDT in D20. Aliphatic and aromatic region 
of interest expanded. Filled circles correspond to CH and CH3, 
open circles correspond to CH2 (Varian INOVA, 600 MHz) 132 
Figure 3.28 HMBC spectrum of Pyronaridine Tetraphosphate 
(PNDT) in D20 (Expansion of the aromatic region only, 
full spectrum given in Appendix G) (Varian INOVA, 600 MHz) 135 
Figure 3.29 1H NMR spectrum of Component Bin DMSO 
(Bruker AVANCE, 500 MHz) 138 
Figure 3.30 13C-Attached Proton Test (APT) of component Bin DMSO 
(Bruker AVANCE, 500MHz) 139 
Figure 3.31 HSQC a.) Aliphatic and b.) Aromatic region 
(Bruker AVANCE, 400 MHz) 139 
Figure 3.32 HMBC spectrum of component B (Bruker AVANCE, 400 MHz) 140 
Figure 3.33 COSY spectrum (aromatic region) (Bruker AVANCE, 400 MHz) 140 
XIV 
Figure 3.34 Schematic model of the formation of hydrogen bonds 
between the N-pyrrolidine ring and 0 20. 146 
Figure 3.35 Stack plot of 1H NMR spectra at the temperature range 
of 25-42°C (coalescence region for diastereotopic hydrogens 
at site 3"/4") (Bruker AVANCE, 400 MHz) 147 
Figure 3.36 Stack plot of 1H NMR spectra at the temperature range 
of 45-65°C (coalescence region for diastereotopic 
hydrogen at site 2"/5") (Bruker AVANCE, 400 MHz) 150 
Figure 3.37 Stack plot of 1H spectra of pyronaridine tetraphosphate (PNOT) at 
temperature range of 5-15 ec, broadening is observed for methylene 
hydrogen at site 1" (Bruker AVANCE, 400 MHz) 152 
Figure 3.38 Variable temperature experiment of PNO in C02Cb. temperature 
range of 25 to -55°C (acquired using JNM-ECA, 600 MHz) 155 
Figure 3.39 Schematic model of the conformation of the pyrrolidine ring 
in the occurrence of inversion ('flip-flop') when 0 20 is diluted. 159 
Figure 3.40 Stack plot of 1H NMR spectra for the mixed solvent 
experiment of pyronaridine tetraphosphate in 
0 20: OMSO (Bruker AVANCE, 400 MHz) 160 
xv 
8 
~G 
CDCb 
CD2CI2 
DMSO 
0 20 
MeOD 
IR 
g 
Hz 
NMR 
MS 
ppm 
s 
PNDT 
PND 
d 
COSY 
TOCSY 
LIST OF SYMBOLS 
Chemical shift 
Gibbs free activation energy 
Exchange frequency/rotation frequency 
Coalescence Temperature 
LIST OF ABBREVIATIONS 
Deuterated chloroform 
Deuterated dichloromethane 
Dimethyl sulphoxide 
Deuterated water 
Deuterated methanol 
Infrared 
gram 
Hertz 
Nuclear Magnetic Resonance 
Mass Spectrometry 
parts per million 
singlet 
Pyronaridine tetraphosphate 
Pyronaridine 
doublet 
Correlation Spectroscopy 
Total Correlation Spectroscopy 
XVI 
HSQC 
HMBC 
NOESY 
DEPT 
Heteronuclear Single Quantum Coherence 
Heteronuclear Multiple Bond Coherence 
Nuclear Overhauser Effect Spectroscopy 
Distortionless enhancement by polarization transfer 
XVII 
ANALISIS PIRONARIDINA DAN PIRONARIDINA TETRAFOSFAT DENGAN 
MENGGUNAKAN KROMATOGRAFI CECAIR PRESTASI TINGGI DAN 
SPEKTROSKOPI RESONANS MAGNETIK NUKLEUS RESOLUSI TINGGI 
ABSTRAK 
Pironaridina (PND), 2-metoksi-7 -kloro-1 0-[3' ,5'-bis-(pyrrolidinil-1-metil)-4'-
hidroksianinilo]benzo[b]-1,5-naftiridina (formula molekul: C29H32CIN502) yang 
disintesiskan oleh Zheng et al pada awal 1970an telah digunakan sebagai ubat 
antimalaria selama 20 tahun. la berwarna merah bata, dengan rasa pahit dan tidak 
berbau dengan takat lebur pada suhu 174-176 °C. Bagi tujuan formulasi ubat, PND 
diubah kepada terbitan fosfatnya iaitu pironaridina tetrafosfat (PNDT) yang terlarut 
dalam air (formula molekul: C29H32CIN502.4H3P04) dan mempunyai takat lebur pada 
227-230 °C. Kajian yang dilakukan ke atas PNDT sebelum ini hanya menunjukkan satu 
puncak pad a kromatogram apabila dianalisis dengan menggunakan kromatografi 
cecair prestasi tinggi (KGPT). Tetapi, dengan menggunakan kaedah terubahsuai 
Jayaraman yang dikembangkan oleh Karupiah (2003), tiga puncak diperhatikan pada 
kromatogram. Tiga puncak ini dilabel sebagai komponen B pad a 10.0 min, X pada 21.2 
min dan Y pad a 24.3 min. Sebatian B diekstrak dan pencirian struktur sebatian 
tersebut dilakukan. Akan tetapi, untuk memastikan identiti komponen B, informasi 
struktur PND dan PNDT perlu ditentukan. Sehingga sekarang, data NMR yang wujud 
hanya daripada spektrum yang dirakam pada 2.11 Tesla (T) (90 MHz untuk 1H). 
Spektra 1H dan 13C pada 1-dimensi dan 2-dimensi dirakam pada 14.2 T (600 
MHz bagi 1H dan 151 MHz bagi 13C). Spektra IR dan MS juga diperoleh untuk 
mengenalpasti struktur sebatian B. Keputusan yang diperoleh mencadangkan bar;3wa 
sebatian B adalah sebenarnya PND tetapi wujud pada konformasi yang berlainan. 
Dalam kajian ini, struktur PND dan PNDT telah ditentukan dengan menggunakan 
kaedah NMR yang berlainan seperti 1H_1H COSY, DEPT, HSQC, HMBC, TOCSY dan 
XVlll 
NOESY dalam pelarut COCb dan DMSO. Spektra yang diperhatikan bagi PNO adalah 
seperti yang dijangkakan mengikut struktur kimianya. Pada bahagian alifatik, empat 
puncak diperhatikan dan pada bahagian aromatik, tujuh puncak diperhatikan. Bagl 
PNDT, spektra NMR diperoleh dengan menggunakan kaedah yang sama tetapi dalam 
pelarut DMSO dan 0 20. Akan tetapi, en am puncak diperhatikan pada bahagian alifatik 
dan bukannya empat. Dua puncak berlebihan tersebut didapati terletak pada proton 
gelang pirolidina (H2"&HS" dan H3"&H4") dengan menggunakan kaedah HSQC. 
Kaedah NOESY juga digunakan intuk mengenal pasti interaksi tanpa ikatan antara 
proton. LlG yang diperlukan untuk proton tersebut bergabung telah dihitung; bagi 
H2"&H5", LlG ialah 15.03 kcallmol dan bagi H3"&H4" ialah 15.33 kcallmol. Nilai 
tersebut dihitung dengan kaedah eksperimen suhu terubah. Kehadiran dua puncak 
yang lebih dalam spektra PNDT adalah disebabkan oleh ikatan hidrogen antara PNDT 
pad a posisi N-gelang pirolidina dan pelarut D20. Untuk membuktikan kesimpulan ini, 
kaedah pelarut tercampur digunakan dimana pelarut DMSO dan 0 20 disediakan pada 
nisbah yang berbeza dan PNDT dilarutkan di dalamnya. Apabila nisbah OMSO yang 
ditambah dalam larutan mencukupi, maka dua puncak akan bergabung menjadi satu. 
Keadaan yang sarna diperhatikan apabila dua pelarut lain iaitu aceton dan metanol 
digunakan. Eksperimen 'deuterium exchange' juga telah dilakukan dalam kajian ini 
bagi menentukan posisi proton bagi kumpulan hidroksi, OH dan am ina, NH pad a 
spektrum NMR bagi PND. 
Kajian ini menunjukkan bahawa komponen B mempunyai struktur yang sama 
seperti PND tetapi pad a konformasi yang berlainan. Maklumat struktur yang lengkap 
bagi PND dan PNDT telah diperoleh daripada kaijian ini dan dapat digunakan sebagai 
rujukan bagi kajian di masa hadapan. 
XIX 
ANALYSIS OF PYRONARIDINE AND PYRONARIDINE TETRAPHOSPHATE 
USING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY AND HIGH 
RESOLUTION NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 
ABSTRACT 
Pyronaridine (PND), 2-methoxy-7 -chloro-1 0-[3' ,S'-bis-(pyrrolidinyl-1-methyl)-4'-
hydroxyanilino]benzo[b]-1 ,S-napthyridines (molecular formula: C29H32CINs02), 
synthesized by Zheng et al. in the early 1970s, has been used in China for over 20 
years as an antimalarial drug. It is an odourless, brick red powder with a bitter taste and 
decomposes at 174-176 °c. For drug formulation purposes, PND is converted to its 
water-soluble tetraphosphate derivative, PNDT (molecular formula: 
C29H32CINs02.4H3P04) that has a melting point of 227-230 °c. All previous studies 
conducted on PND and PNDT using HPLC showed only one peak present in the 
chromatogram. However, the modified version of Jayaraman's HPLC method 
developed by Karupiah (2003) showed the presence of three peaks. These were 
labelled as component B at 10.0 min, X at 21.2 min and Y at 24.3 min. Component B 
was then extracted and characterized. However, in order to ascertain its identity, 
detailed structural information of both PND and PNDT must first be established. To 
date, the only NMR data available in literature on PND was deduced from a proton 
spectrum recorded at 2.11 Tesla (T) (90 MHz in lH). 
i-Dimensional and 2-Dimensional 1 H and DC NMR spectra of both PND and 
PNDT were recorded at 14.2 T (600 MHz in 1H and 1S1 MHz in 13C) and 9.S T (400 
MHz) in this research. In addition, IR and MS were also performed to identify 
component B. The results suggest that component B maybe a different conformation of 
pyronaridine. In this research, the structure of PND and PNDT were obtained under 
different NMR techniques such lH_1H COSY, DEPT, HSQC, HMBC, TOCSY and 
xx 
NOESY in CDCb and DMSO. The spectra correspond to the diastereotopic protons on 
the pyrrolidine ring with the aid of HSQC technique. Nonbonded interactions between 
the methylene protons at 1" and certain aromatic protons were established using 
NOESY technique. In addition, the free molar activation energy, ~G required for the 
singlets corresponding to the diastereotopic protons to coalesce was calculated to be 
at 15.33 kcal/mol for H3" & H4" and 15.03 kcal/mol for H2" & H5" using variable 
temperature experiments. The presence of the two extra resonances is believed to be 
caused by the formation of hydrogen bond between D20 and the N centre at the 
pyrrolidine ring. To confirm this deduction, mixed solvent experiments were employed. 
Different solvents namely DMSO, acetone and methanol were added individually to the 
PNDT sample in D20, and the two singlets corresponding to the diastereotopic protons 
were observed to coalesce to form only one peak. The same was observed in the 
acetone and methanol experiment respectively. This is believed to occur due to the 
disruption of the hydrogen bond between D20 and the N centre. Deuterium exchange 
study was conducted on PND in DMSO to confirm the acidic OH and NH position in the 
NMR spectrum. 
From this study it is concluded that component B is observed to have the same 
structure as PND and just conformationally different. Comprehensive structural data 
for PND and PNDT was established from this research and can be used as a reference 
to many other researchers who would be interested in studying this drug in the future. 
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CHAPTER ONE 
INTRODUCTION 
1.1 Ma!aria 
Malaria, a protozoal disease caused by the parasite Plasmodia and spread by 
the Anopheles mosquito is a very old disease thought to originate in Africa. 
(www.rph.wa.gov.aullabs/haem/malaria/historv.html). There are 500 million cases and 
nearly three million deaths annually, where most cases occur in sub-Saharan Africa 
(Beer et a/., 2006). The spread of malaria is usually associated with factors such as 
global changes including deforestation, mass migration due to war, mining and such. 
The main factor that contributes to the spread of this disease is the emergence of drug 
resistance in P.falciparum (Rosenthal, 1998; Taylor-Robinson, 2000). However, the 
actual cause of drug resistance is not known to be due to drug pressure and increase 
in infection reservoir (Lines et a/., 1991) or due to intrinsic parasite characteristics (Giha 
et a/., 2006). In the United States and Western Europe, most malaria infections are 
imported by travellers and due to the increase in globalisation of commerce, the 
number of travellers to areas of high risk is increasing each year (Wirth, 1999). 
1.2 Status of Malaria in Malaysia 
Malaria remains the most common vector-borne parasitic disease in Malaysia 
despite a decrease in the annual number of cases (Singh & Singh, 2001). The 
topography, the climate, and the migrations of the people due to increased economic 
activity are similar in peninsular Malaysia, Sabah, and Sarawak. However, the situation 
is different from area to area in terms of species of vectors, distribution of parasitic 
species, and resistance of Plasmodium falciparum to chloroquine. The problems faced 
by the suppression or control programs in the three regions are different (Rahman, 
1982). In 1993, 39 890 cases were reported, 24.3 % in West (Peninsular) Malaysia and 
the remainder in East Malaysian states, particularly Sabah (73.0 %) where 65 % of the 
infections were caused by Plasmodium falciparum (Hakim et aI., 1996). Malaria cases 
in the early 1990's were around 50,000, with a steady decline to 6050, 5096 and 1770 
for years 2001, 2002 and 2003, respectively (Vythilingam et aI., 2005) 
Plasmodium falciparum is the most predominant species in Malaysia with 
P. vivax and P.malariae being the next widespread species (Singh & Singh, 2001). The 
distinction between the three geographically distinct regions: Peninsular Malaysia, 
Sabah and Sarawak, in the number of malarial cases and the distribution of 
Plasmodium species are depicted in Table 1.1 (Singh & Singh, 2001). In the study 
conducted by Vythilingam et al. (2005), where the impact of development and malaria 
control activities on the vectors in Sabah were studied, cases of malaria decreased at 
significant levels in three out of six of the test villages (P < 0.05) and no positive 
mosquitoes were obtained. Children were more prone to malaria as they have not 
developed immunity. It can be concluded that both integrated malaria control 
programmes coupled with the removal of habitat have acted to reduce malaria cases 
along with the primary vector An. balabacensis in Sabah. 
The increase of malarial cases is linked to an increase in the incidence of drug 
resistant parasites. Chloroquine and sulphadoxine/pyrimethamine show widespread 
resistance in the endemic areas of West Malaysia where a slight increase in the overall 
resistance is observed for chloroquine (51 % to 64 %) and the increase for severe 
resistance was from 4 % to 55 % (Hakim et al., 1996). Mefloquine is also used in 
combating multidrug resistant falciparum malaria in Malaysia and has been proven 
effective (Lim et aI., 1994), however in Thailand the development of resistance towards 
this antimalarial is observed (Hakim et al., 1996). 
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Table 1.1: Distribution of the different human malaria species in Malaysia for 1995 and 
1999 (Singh & Singh, 2001). 
Species Peninsular Sabahc I Sarawako Malaysia 
Malaysiab , 
-_ .. __ ._-- ----_._. ..... __ . __ .-._-
1995 1999 1995 1999 , 1995 1999 1995 1999 
Plasmodium 3740 1712 30999 3052 
, 
411 786 35150 5550 
fa/ciparum 
Plasmodium 3751 1712 15858 1207 959 2031 20568 4950 
vivax 
Plasmodium 16 23 615 75 207 269 838 367 
malariae 
Plasmodium 0 0 0 0 0 0 0 0 
o vale 
Mixed 245 46 2393 124 14 69 2652 239 
species 
Total 7752 3493 49865 4458 1591 3155 59208 11106 
"Annual number of mlcroscopy-confinned cases of malana for Peninsular Malaysia, Sabah, Sarawak and the total 
number for Malaysia. 
bTaken from Vector-Borne Diseases Section, 1999 Annual Report, Division of Disease Control, Dept of Public Health, 
Ministry of Health 
Malaysia. 
"Taken from Sabah State Vector-Borne Diseases Control Programme 1999 Annual Report. 
"Taken from Sarawak State Vector-Borne Diseases Control Programme 1999 Annual Report. 
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1.3 Malaria Pathology 
1.3.1 Species 
Malaria is caused by the protozoan parasite, Plasmodium, a member of the 
phylum Apicomplexan. The four species for the malarial parasite that infect man are: 
i.) P.falciparum 
ii.) P.malariae 
iii.) P.ovale 
iv.) P. vivax 
P. vivax and P.ova/e malaria invade immature young erythrocytes, whereas 
P.ma/ariae infect mature cells and P.falciparum infects cells of all stages (Murray & 
Perkins, 1996). P.fa/ciparum can cause death as a result of cerebral malaria, 
pulmonary or renal failure. P. vivax is also a common cause of human malaria, 
especially in South East Asia and in Central and South America. Patients who contract 
this form of malaria may become very ill with severe clinical symptoms. The other two 
forms of human malaria account for about 5-10 % of the cases of malaria. Both P. vivax 
and P.ovale are associated with relapsing malaria as both parasites are able to deposit 
a dormant form in the host's liver. This form is called the hypnozoites that may awake 
at anytime and produce merozoites that invade the blood 
(WWIN.malariasite.com/malaria.html). 
1.3.2 Life Cycle 
Malaria infection is initiated by the bite of an infected Anopheline mosquito 
(Croft, 2000). Malaria parasites are transmitted to mosquito vectors inside the 
vertebrate host where the asexual-stage parasites change to gametocytes (Bannister & 
Mitchel, 2003). The sexual differentiation occurs during the asexual erythrocytic cycle 
and this then precedes to gametocyte formation (Smith, 2002). However, certain pre-
erythrocytic merozoites that are derived from hepatic schizonts (Frevert, 2004) are 
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known to form gametocytes (Bannister & Mitchel, 2003). P.fa/ciparum possesses one 
of the fastest DNA replication rates of all eukaryotic cells (Li & Cox, 2003). In P. vivax 
and P.ova/e malaria the young blood cells are infected, in P.ma/ariae the mature red 
cells are infected and in P.falciparum malaria cells of all stages are infected. In 
P.fa/ciparum, the parasites multiply very rapidly and occupy 30 % or more of the red 
blood cells causing a very significant level of haemolysis 
(www.rph.wa.gov.aullabs/haem/malaria/historv.html). Merozoites from erythrocytic 
schizonts develop into either all asexual-stage or all sexual-stage parasites. From this, 
each schizont produces either male or female gametocytes (Smith et aI., 2002). In 
P.falciparum, gametocytogenesis occurs over approximately eight days and passes 
through 5 morphologically different sub stages (Day et al., 1998; Talman, 2004). The 
other plasmodium species undergo gametocyte development that is proportional to the 
duration of the sexual cycle, which is between one and three days (Day et al., 1998). 
It is during this sporozoites portion of the life cycle that genetic exchange can 
occur between different parasites. The obligate sexual exchange, which occurs at each 
transmission cycle, is thought to playa major role in the rapid spread of traits such as 
drug resistance throughout parasite populations (Yepuri, 2004). The asexual cycle 
takes about 48 hours for one cycle for all the species (72 hrs for P.ma/ariae) where 
each merozoite divides into 8-32 (average 10) fresh merozoites 
(www.malariasite.com/malaria/Evolution.htm). Sexually committed merozoites escape 
host erythrocytes when the schizont ruptures and invade new erythrocytes where they 
grow into trophozoites which then transform into gametocytes (Bannister & Mitchel, 
2003). All stages of development subsequent to the liver are observed in the peripheral 
blood for P.vivax, Favale and probably P.malariae. However, for PJafciparum, only 
ring forms and gametocytes are usually present in the peripheral blood where as the 
developing forms appear in the blood vessels of larger organs such as the brain, which 
restrict the blood flow (www.rph.wa.gov.au/labs/haem/malaria/history.html). 
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6 
1.4 Biological classification of antimalarial drugs 
Antimalarial drugs have their own effects and modes of interaction according to the 
various stages of the parasites life cycle. Therefore, these drugs can be categorised 
according to these modes of actions on the specific stages of the malaria parasite life 
cycle namely: 
i.) Tissue schizontocides 
ii. ) Hypnozoites 
iii.) Schizontocides 
iv.) Gametocides and 
v.) S porontocides 
(Bruce-Chwatt, 1986; Kumar et al., 2003) 
Drugs that are classified as Tissue schizontocides for causal prophylaxis act on the 
primary tissue forms of the plasmodia. These tissue forms of the plasmodia are 
responsible for the initiation of the erythrocytic stage. Therefore, blocking of this stage 
allows prevention of further development of the infection. Pyrimethamine and 
primaquine are commonly used as tissue schizontocides. However since it is 
impossible to predict the infection before clinical symptoms begin, this mode of therapy 
is more theoretical than practical. 
Drugs classified as Tissue schizontocides for preventing relapse act on the 
hypnozoites of P. vivax and P.ovale in the liver that cause relapse of symptoms on 
reactivation. Primaquine is the prototype drug and pyrimethamine also has such 
activity. Blood schizontocides drugs act on the blood forms of the parasite and thereby 
terminate clinical attacks of malaria. These are the most important drugs in malarial 
chemotherapy and they include chloroquine, quinine, mefloquine, halofantrine, 
pyrimethamine, sulphadoxine and pyronaridine. Pyronaridine is the drug of interest in 
this thesis and will be discussed in detail in section 1.6. 
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Gametocytocide drugs destroy the sexual forms of the parasite in the blood and 
thereby prevent transmission of the infection to the mosquito. Chloroquine and quinine 
have gametocytocidal activity against P. vivax and P.malariae, but not against P 
fa/ciparum whereas primaquine has gametocytocidal activity against ali plasmodia, 
including P. fa/ciparum. Drugs classified as Sporontocides prevent the development of 
oocysts in the mosquito and thus ablate the transmission 
(http://www.malariasite.com/malaria/antimalarialdrugs.htm). The antimalarial drugs 
that are most commonly used will be discussed in detail in the section below. 
1.5 Antimalarial Drugs 
This section discusses the various antimalarial drugs that are important and 
currently used in the prophylaxis and treatment of malaria infection. 
1.5.1 Quinine 
Quinine is one of the longest used drugs in the treatment of malaria. Its 
derivative is chloroquine and other analogues include amodiaquine, mefloquine and 
halofantrine. These drugs are blood schizontocides and their mechanism of action is 
through accumulation in the acidic food vacuoles of trophozoite-infected cells, thereby 
preventing haemoglobin production in the organelle. Quinoline inhibits the heme 
polymerase enzyme resulting in specific toxicity during the parasite development 
(Slater & Cerami, 1992). 
Quinine is commonly used in areas where P.fa/ciparum shows resistance to 
chloroquine and sulphadoxine/pyrimethamine combination (Wernsdorfer & Pyne, 
1991). Quinine's monotheraphy has been associated with a failure rate of 40-70 % in 
South East Asia and Africa (White, 1992). Due to the increase in the degree of 
resistance tOvvards this drug, it is usually given in combination with tetracycline for a 
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period of seven days. The cure rate observed for this drug is between 90 to 98 % 
(Looareesuwan et al., 1996). 
Quinine has antipyretic, antimalarial and analgesic properties and it is also a 
stereoisomer of quinidine and it has a bitter taste. The theorised mechanism of action 
for quinine is that it is toxic to the malaria parasite. It specifically interferes with the 
parasites ability to degrade and digest haemoglobin, thus starving the parasite. It would 
also cause the build-up of toxic levels of partially degraded haemoglobin in the 
parasite. Use of quinine in therapeutic doses may cause cinchonism (i.e. ringing in the 
ears, nausea, vomiting) when used in excessive doses or in rare cases it may even 
calise death by rapid pulmonary oedema (www.malariasite.com/malaria/guinine.htm). 
1.5.2 Chloroquine 
Chloroquine is a 9-aminoquinoline that has been known since 1934 and was 
synthesised as an antimalarial agent. However, due to its immunomodulatory 
properties, this drug has also been used in the treatment of autoimmune diseases such 
as rheumatoid arthritis (Savarino et al., 2003). Chloroquine is widely used to treat all 
types of malarial infections. Its chemical formula is C18H26CIN3 with a molecular weight 
of 391.877 g/mol. Chloroquine is also known as N(sup 4)-(7-chlor0-4-quinolinyl)-N (sup 
i), N (sup 1)-diethyl-1,4-pentadiamine. As an alkaline drug, it reaches high 
concentration within the food vacuoles of the parasite and raises its pH 
(www.malariasite.com/malaria/chloroguine.htm). Chloroquine interferes with the 
parasites haem degradative pathway and thereby it prevents detoxification of harmful 
products from the metabolism (Slater, 1992). P.fa/ciparum is resistant to chloroquine in 
all endemic areas except Central America (Winstanley et al., 2002). 
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1.5.3 Mefloquine 
Mefloquine is a 4-aminoquinoline methanol structurally related to quinine 
(Cerami et al., 1992) Mefloquine is an orally administered antimalarial and it is 
commonly known as mefloquine hydrochloride (formulated with HCI). Its chemical 
name is [2,8-bis(trifluoromethyl)quinolin-4-yl]-2(piperidyl)methanol. The chemical 
formula is C17H16F6N20 with a molecular mass of 378.312 g/mol 
(http://en.wikipedia.org/wikilMefloquine).ltis administered orally and has a long half life 
that results in the emergence of drug resistance (White, 1992). 
MefJoquine is selectively active against the intraerythrocytic mature forms 
(trophozoite and schizonts) of malaria and has no activity against gametocytes (Palmer 
et al., 1993). Mefloquine produces swelling of the P.fa/ciparum food vacuoles. It may 
act by forming toxic complexes with free heme that damage membranes and interact 
with other plasmodial components. It is effective against the blood forms of fatciparum 
malaria, including the chloroquine resistant types. Mefloquine is absorbed rapidly and is 
extensively bound to plasma proteins and it has an elimination half-life of 2-3 weeks 
(lNWW.malariasite.com/malariaimefloquine.htm). 
MefJoquine is used for prophylaxis and chemotherapy of chloroquine-resistant 
P.falciparum malaria 48 hours after the parasite burden has been reduced by prior 
administration of an artemisinin antimalarial (White, 1999). Large trials conducted on 
mefloquine suggest that it is generally well tolerated. However, adverse effects have 
been reported such as diarrhoea, dysphoria, anorexia, vivid dreams, headache, 
changes in sleep, hallucinations and late vomiting (Albright et at., 2002). 
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1.5.4 Halofantrine 
Related to mefloquine is the other analogue of quinine, which is halofantrine, a 
phenanthrene methanol analogue that is an addition to the treatment of MDR 
P.fa/ciparum (Dvorak et a/., 1975). Halofantrine is an effective drug for the treatment of 
malaria and is often recommended against infections with chloroquine or 
pyrimethamine resistant P.fa/ciparum strains (Cosgriff et a/., 1982). Its chemicals name 
is 1-(1 ,3-dichloro-6-trifluoromethylphenanthyl)-3-N,N-dibutylaminopropan-1-01 (Kolade 
et a/., 2005). 
Its mechanism of action may be similar to that of chloroquine, quinine and 
mefloquine that is by forming toxic complexes with ferritoporphyrin IX that damage the 
membrane of the parasite. The peak plasma concentration is achieved in 4 to 8 hours 
after the oral dose with elimination half-life of 1 to 3 days for the parent drug and 3 to 7 
days for the active metabolite. It is used in the treatment of chloroquine resistant and 
multi-drug resistant, uncomplicated P.falciparum malaria 
(http://en.wikipedia.org/wiki/halofantrine.htm). Cardiotoxicity has become a major 
concern during treatment with this drug where lengthening of the QTc (Q and T wave 
correction in cardiac cycle) and severe cardiac arrhythmia have been observed (Touze 
et a/., 2002). 
1.5.5 Amodiaquine 
For the past 20 years, amodiaquine has been known to show higher cure rates 
even though there is cross-resistance between amodiaquine and its close congener, 
chloroquine (Winstanley et al., 2002). Amodiaquine (AQ) is synthesized from 4,7-
dichloroquinoline and 4-acetamido-diethylamino-o-cresol or an alternative synthesis 
from 2-aminomethyl-p-aminophenol and 4,7-dichloroquinoline. Its chemical name is 4-
[7 -dichloro-4-quinolyl)aminoJ-2-[( diethylamino )methyl]phenol dihydrochloride dihydrate 
and the structural formula is C2oH22CIN30,2HCI,2H20. Amodiaquine hydrochloride is a 
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yellow crystalline powder that is odourless with a bitter taste and molecular weight of 
464.8 g/mol. The decomposition point for AQ is at 150-160 DC 
(www.inchem.org/documents/pims/pharm/amodiggn.htm). When used over a long 
period of time, amodiaquine has been observed to cause agranulocytosis and hepatitis. 
However, there is limited evidence as to whether amodiaquine is toxic when used for 
treatment in a 25/mg/kg dose over three days (Winstanley et al., 2002). 
1.5.6 Pyrimethamine/Sulphadoxine 
Antimetabolites are divided into two types, based on mode of action, and exert 
their activity on the folic acid cycle. Type one includes sulpha drugs such as 
sulphadoxine and type two include pyrimethamine and cycloguanil (Warhurst, 1986). 
Sulphadoxine-pyrimethamine is sometimes considered as a single drug rather than a 
combination, although they have different modes of action. Pyrimethamine inhibits the 
dihydrofolate reductase whereas sulphadoxine inhibits dihydropteroate synthase 
(DHPS). The inhibition of both these enzymes prevents the synthesis of folic acid in the 
parasite (Kremsner & Krishna, 2004). The resistance in parasites are increased when 
sulphadoxine is used as monotheraphy due to the mutations that occur in the gene 
coding for DHPS (Plowe, 2001). It was thus combined with pyrimethamine to inhibit 
folic acid formation. Sulphadoxine has an elimination half-life of 120 hours in children 
(Kremsner & Krishna, 2004). 
1.5.7 Chloroguanide 
Chloroguanide or more popularly known as proguanil was developed by the 
British antimalarial research in 1945. It is a biguanide derivative that is converted to an 
active metabolite called cycloguanil pamoate. It exerts its antimalarial action by 
inhibiting parasitic dihydrofolate reductase enzyme. It has prophylactic and suppressive 
activity against P.falc;parum and can cure acute infection. It is effective in suppressing 
the clinical attacks of v;vax malaria, however it is slower compared to 4-
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aminoquinolines. Peak plasma levels are achieved within 5 hours and the elimination 
half-life is 16 to 20 hours (www.malariasite.com/malaria/chloroguanide.htm). 
1.5.8 Artemisinin Derivatives 
Antimalarial activity against both P. falciparum and P. vivax has been identified 
from the traditional Chinese plant Artemisia annua L. (Chawira et a/., 1987). Artemisinin 
is the active principle of the herb artemisia annua. The active antimalarial constituent of 
this compound was isolated in 1971 and named artemisinin. Artemisinin, a 
sesquiterpene lactone has a molecular formula of C15H2205 and molecular mass of 
282.332 g/mol. Its chemical name is (3R, 5aS,6R,8aS,9R,12S,12aR)-octahydro-3,6,9-
trimethyl-3, 12-epoxy-12H-pyrano[4,3-j]-1 ,2-benzodioxepin-1 0(3H)-one and has a 
melting point of 152-157 DC. The NMR structure of artesunate has been established 
(Ruscoe et a/., 1998; Robert et a/., 2002). 
Structurally, artemisinin is unrelated to any other antimalarial and problems 
related to high rates of recurrence of the disease, its low solubility, short plasma life 
and poor oral bioavailability prompted the investigations into the discovery of other 
derivatives with better physiochemical properties (Lee & Huffard, 1990; Lin & Miller, 
1995). The derivatives are artesunate, a water-soluble ester together with oil soluble 
artemether and arteether, all of which have in vitro and in vivo activity against 
erythrocytic forms (blood schizonts) of malaria (Barradell & Fitton, 1995; Lin & Miller, 
1995). Artemether and artesunate have activity that decreases after one to 1\.'10 hours, 
however by giving artemisinin alongside lumefantrine or mefloquine or amodiaquine 
solves this drawback. Such a treatment is called ACT (artemisinin-based combination 
therapy) (www.malariasite.com/malaria/artemisinin.htm). The combination of 
artemisinin and mefJoquine is more effective than artesunate monotheraphy as it 
decreases the rate of recurrence and Improves the overall cure rate (90-100 %) (Kain, 
1995). 
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Artemisinin related compounds are concentrated in parasite-infected 
erythrocytes and the bridging endoperoxide group appears to be crucial for anti 
malarial activity (Barradell & Fitton, 1995). The antioxidant effect is critical for parasite 
survival, thus the anti-malarial activity of artemisinin compounds is mediated by 
increasing the levels of activated oxygen radicals (Barradell & Fitton, 1995; Meshnick, 
1994). 
1.5.9 Lumefantrine 
Lumefantrine was first synthesized in China and is now available commercially 
only in the co-formulated form with artemether (Annerberg et al" 2005). It is a highly 
lipophilic compound and is bound to plasma proteins at more than 99.9 % (Colussi et 
al., 1999) and has variable absorption (Ezzet et al., 2000). It has proven to be well 
tolerated and has high efficacy in children and adults with multidrug resistant strains of 
P.falciparum (Annerberg et al., 2005). 
1.5.10 Primaquine 
Primaquine is an 8-aminoquinoline antimalarial. Its chemical name is N-(6-
methoxyquinolin-8-yl)pentane-1,4-diamine and the molecular structure is C1sH21N30. 
Primaquine is active against various stages of the malaria parasite. It kills the latent 
and developing asexual stages in the liver and also sterilizes the gametocytes. A 
standard regimen of primaquine would clear the blood of asexual trophozoites of 
P. vivax (Pukrittayakamee et al., i 994; Wilairatana et al., 1999). However, the same is 
not observed for P.falciparum (Baird et al., 2002). The mechanism of action of this 
antimalarial is unclear, however the various metabolites that are present in it are 
believed to disrupt the parasites mitochondrial membranes (Warhurst, 1984). 
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1.6 Pyronaridine Tetraphosphate (PNDT) 
1.6.1 Introduction 
Pyronaridine tetraphosphate, 2-methoxy-7 -chloro-1 0-[3' ,5'-bis-(pyrrolidinyl-1-
methyl)-4'-hydroxyanilino]benzo[b]-1 ,5-napthyridines, an anti-malarial drug synthesized 
by Zheng et al. in the early 1970s, has been used in China for over 20 years (Zheng et 
al., 1979; Feng et a/.,1987). It has been reported to be effective against not only 
chloroquine-resistant but also multi drug resistant P.falciparum without major side 
effects (Looareesuwan et al., 1996; Ringwald, 1996). 
A review of novel and therapeutically used compounds revealed that many anti-
malarial agents contain a 4-aminophenol group, which may influence their toxicological 
profile. These compounds, analogues of amodiaquine, can be classed as Mannich anti-
malarial agents due to the incorporation of an amine group in their side chains. 
Pyronaridine tetraphosphate (PNDT), also known as a bis-Mannich anti-malarial 
substituted at the C-5' with a pyrrolidine group and an acridine rather than a quinoline 
nucleus has already been used effectively in the treatment of resistant strains of 
P.fa/ciparum both in vitro (Ruscoe et al., 1998) and in the clinic (Peters & Robinson, 
1992). 
Mannich base anti-malarial drugs are broadly classified into two groups: 
quinoline-type. e.g., amodiaquine and amopyroquine, and acridine-type, e.g., 
pyronaridine and pyracrine. Despite common chemical features, they differ 
substantially from chloroquine and amongst themselves in their activities, rate and 
stability of resistance (Shao, 1990). The presence of the hydroxyanilino moiety would 
cause PNDT to share toxicity problems with its congener, amodiaquine. This group has 
been implicated in agranulocytosis associated with the prophylactic use of the drug. but 
not repolied for treatment (Winstanley, 1996). 
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1.6.2 Chemistry of Pyronaridine (PND) 
Pyronaridine (PND) is the product of a nine-step synthesis from 2-amino 
pyridine. The last synthetic step is a Mannich reaction to add two pyrrolidinyl-1-methyl 
substituents. PND is then treated with phosphoric acid to give PNDT, of molecular 
weight 910 (content in PND base = 57 %). An abbreviated synthesis from commercially 
available 2-methoxy-5-aminopyridine is also possible (Chen et al., 1992). 
PNDT occurs as a hygroscopic yellow powder, odourless, with a bitter taste. It 
is soluble in water, very sparingly soluble in ethanol, and insoluble in chloroform, ether, 
and other organic solvents. PNDT has been used experimentally and in clinical 
treatment of malaria. All dosages of PNDT have been calculated as the free base 
(PND). The drug has been produced as tablets and injectable liquid and it can be 
administered by the oral, intramuscular routes and intravenous drips (Olliaro, 2000). 
Ruscoe et al. (1998), have studied the effects of chemical modification on the 
disposition of Mannich antimalarial agents in their pharmacology and toxicology. It was 
evident from the study that increases in the lipophilicity and basicity by the C-5' position 
of amodiaquine had a profound effect on the ability to accumulate and reside within 
tissues. The increase in the tissue residency time of C-5' substituted compounds 
increases the duration of their pharmacological activity through maintenance of 
therapeutically active concentration in plasma. 
1.6.3 Synthesis of PND 
The schematic representation for the synthesis of PND is shown in Figure 
1.4. Pyronaridine is synthesised from 2-aminopyridine. 2-aminopyridine (1) is reacted 
by mononitration at position 5 to obtain 2-amino-5-nitropyridine (2). 2-hydroxy-5-
nitropyridine (3) was synthesized by hydrolysis of (2). Chlorination of (3) would yield 2-
chloro-5-nitropyridine (4). Compound (4) could also be obtained by diazotisation of (2) 
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followed by treatment with C2C12. Compound (4) can also be produced from pyridine (5) 
by oxidation to form N-methylpyridine-2-one (6), which was subsequently nitrated and 
pursued by chlorination to derive (7). 
Compound (4) was then reacted with sodium methoxide to obtain 2-
methoxy compound (8), which was reduced to give 5-amino compound (9). 
Condensation with 2,4-dichlorobenzoic acid was performed to produce 2-methoxy-5-
(2'-carboxy-5'-chlorophenyl)aminopyridine (10). 2-methoxy-7,10-dichlorobenzo(b)1,5-
napthyridine (11) was formed after cyclisation of (10), (11) was followed by 
condensation with p-aminophenol to derive 2-methoxy-7 -chloro-1 0(4'-
hydroxyphenyl)aminobenzo-(b)1,5-naphthyridine(12). The latter was reacted with 
Mannich reagent to produce pyronaridine (13), melting point at 174-176 °C 
(decomposition). This was then reacted with phosphoric acid to yield pyronaridine 
tetraphosphate, melting point at 233-236 °C (decomposition) (Chen et al., 1992). 
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Figure 1.4: Schematic diagram of synthesis of PND and its simplified structural formula 
(Chen et al.. 1992). 
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1.6.4 Analysis of PND 
Wages et al. (1990), described a high performance liquid chromatographic 
method with oxidative electrochemical detection using an analogue of amodiaquine as 
an internal standard to quantify pyronaridine in rhesus monkey blood and urine 
samples. This method would be applied in support of clinical and pharmacokinetic 
studies to evaluate the prospects of using this drug outside of China. The 
chromatograms from the study showed only one peak corresponding to pyronaridine 
tetra phosphate in both the blood and urine samples. 
Saleh and Loh, (1993), developed a reversed-phase liquid chromatographic 
method for the determination of the antimalarial drug pyronaridine in plasma. A UV 
detector was used in this study. Pyronaridine, which is basic, was shown to be very 
dependent on the hydrogen ion concentration for extraction or separation by reversed-
phase LC. The method developed was suitable for the analysis of human, rat and 
monkey plasma and whole blood samples. The chromatograms produced only one 
peak corresponding to pyronaridine. 
Jayaraman et al. (1997), described a method for the determination of 
pyronaridine in human plasma using high performance liquid chromatography with 
fluorescence detection. It involved the isolation of pyronaridine from plasma samples by 
liquid-liquid extraction followed by HPLC separation and determination. A typical 
chromatogram of pyronaridine standard and quinine internal standard showed one 
peak corresponding to each compound. The same was observed in spiked plasma 
samples. The assay procedure was adequately sensitive to measure 10 ng/ml 
pyronaridine in plasma samples with acceptable precision «15 %) and found to be 
suitable for use in clinical pharmacological studies. 
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Chen and Fleckenstein (2001), conducted an improved assay method using 
HPLC for the determination of PNDT in plasma and whole blood. The internal standard 
used in this study was amodiaquine owing to its similar structure to PNDT, where good 
recovery from plasma (88.7 %) and from blood (85.4 %) and larger retention time 
compared to PNDT was observed. Amodiaquine was considered as less likely to 
interfere with identification of more water-soluble metabolites of PNDT in future 
pharmacokinetic studies. One peak corresponding to pyronaridine tetraphosphate was 
detected in the standard, in the plasma spiked with PNDT and blood sample spiked 
with PNDT. The method proved to be sensitive, selective and specific. 
Babalola et al. (2003), developed a method for the determination of 
pyronaridine in human plasma and oral dosage form. Reversed phase HPLC with UV 
detection at 278 nm was described involving liquid-liquid extraction of the drug followed 
by basification of the deproteinized plasma with alkaline phosphate buffer. Preliminary 
pharmacokinetic data demonstrate the principal applicability of the method for clinical 
trials of the drug, especially in malaria endemic regions such as Africa. The assay 
could also be applied for the analysis of pyronaridine formulations without extraction 
process. 
A new approach using solid-phase extraction technique was developed for the 
determination of pyronaridine and the analysis was performed using reverse phase 
chromatographic method with fluorescence detection. Three chromatographic peaks 
were resolved after injection of PNDT solution and the same was observed for the 
capsule formulation. These unknown peaks were labelled as 1,2 and 3. Compound 3 
was successfully extracted using column chromatography and characterized using 
mass spectrometry and NMR to be PND. This method was found to be suitable for use 
in clinical pharmacokinetic studies (Ramanathan et a/., 2005). 
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Table 1.2: Summary of methods of analysis for Pyronaridine tetraphosphate 
Researcher (Year) Equipment Extraction Solvent 
Feng & Wang (1986) 
Wages et aI., (1990) 
Saleh & Loh, (1993) 
Spectrofluorometry, Aex = n-Heptane:lsoamylalcohol 
394 nm and Aem = 458 nm (98:2, v/v) 
HPLC 
detector 
-electrochemical Ethyl acetate 
HPLC - UV at A = 278 nm Diethyl ether 
Column and Mobile Phase 
Polymer PRP-1, 10 Ilm 
MeOH: H20 (34:66,v/v), 
PH 2.8 with 1 % TEA 
Limit of Detection 
10 ng/ml 
20 ng/ml 
Partisil -10, ODS C18, 10 Ilm, 70 ng/ml 
Acetonitrile: Phosphate buffer 
0.08M (15:85, v/v) , pH 2.0 
with 1% TEA 
Jayaraman et aI., (1996) 
. Nucleosil, C18, 10 Ilm, 
HPLC - Fluorescence, Aex = Dlethyl ether: hexane (70:30, Acetonitrile: Phosphate buffer 10 ng/ml 
267 nm and Aem = 443 nm v/v) 0.05 M (60:40,v/v), pH 6.0 
Chen & Fleckenstein 
(2001 ) 
Babalola et aI., (2003) 
Ramanathan et aI., (2005) 
HPLC - UV at A = 275 nm 
HPLC - UV at A = 278 nm 
HPLC - Fluorescence, Aex = 
267 nm and Aem = 443 nm 
____ ._. ___ . ___ " __ ..... _._0 .. ____ -------------------
Diethyl ether 
Diethyl ether 
C-18 solid phase sorbent 
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Zorbax Bonus, diisopropyl-
C14, Acetonitrile: Phosphate 
buffer 0.08M (13:87, v/v) , pH 3 ng 
2.8 
Microbore 
0.1 %TFA:Acetonitrile 
(75:25%, v/v), pH 2.2 
C18. 
Partisil 10 ODS, 
MeOH:0.05M Ammonium 
actetate buffer (50:50, v/v) , 
pH 4.0 
50 ng/ml 
10 ng/ml 
1.6.5 In vitro and In vivo Activities 
The nitrogen atom at position 1 and pyrrolidinyl Mannich base side chains on 
the structure plays an important and indispensable role for antimalarial activity of 
PNDT, Figure 1.1. The pyrrolidinyl Mannich bases impart increased activity to the 
corresponding compounds (Chen, 1993). 
PNDT is a blood schizontocide, Le., it acts on asexual blood stage parasites. 
Gametocytocidal activity has been reported in vitro, but only limited efficacy is reported 
in vivo (Shao, 1990). Its mechanism of action remains unclear. Initial data suggested 
that the target of PND, and other 9-anilinoacridines, was the parasite topoisomerase II 
(Chen, 1981). However, further experiments with acridine analogues, known inhibitors 
of topoisomerase II, contradicted this initial hypothesis (Chen et a/., 1993). Its mode of 
action has been studied using rats infected with P.berghei strain where pyronaridine 
was administered at a dose of 20 mg/kg (Wu et a/., 1998). The early changes detected 
were the modifications to the morphology of trophozoites. During these changes, 
pellicular complexes form in which multilamellate whorls appear, followed by 
enlargement of pigment aggregation in the food vacuoles. The mitochondria become 
swollen, the endoplasmic reticulum disappears and ribosomes become blurred. Thus 
for in vitro, the food vacuole of the malaria parasite may be the primary target of PNDT 
(Fu & Xiao, 1991). 
It is possible that PNDT acts via a mechanism that is common to other 4-
aminoquinolines by interfering with heme metabolism, probably by blocking hemazoin 
formation. Electron microscopy findings confirm that the parasites digestive system is 
targeted (Looareesuwan et al.,1996). The in vitro interactions of artemisinin with 
amodiaquine, pyronaridine and chloroquine for the treatment of PJa/ciparum were 
studied by Gupta et at. (2002). Pyronaridine generally showed at least additive activity 
but predominantly moderate synergism with artemisinin. The results observed in this 
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